Thank you for downloading!
Check out more content that may interest you and follow us on social media
The latest from Median
Median Technologies has officially commenced operations with all investigator sites participating in the pivotal validation plan for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx Software as Medical Device (SaMD).
Median reports today its business indicators for the first half of 2023 for the iCRO activity and the iBiopsy® activity. The Company also announces the first step of ths refinancing plan.
The study showed that CT-based radiomics can accurately predict the histopathological subtype of NSCLC patients, offering a less invasive and more cost-effective alternative to traditional tissue analysis methods.
AI-powered medical image analysis has the potential to serve as predictive biomarkers for guiding targeted therapies in the future
Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!
Conferences
20 – 24 October, 2023ESMO 2023
Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!
